Scientists At Johns Hopkins University Target Ovarian Cancer

Paclitaxel has been widely used as an anti- mitotic agent in chemotherapy for a variety of cancers and adds substantial efficacy as the first-line chemotherapeutic regimen for ovarian cancers. However, the frequent occurrence of paclitaxel resistance limits its function in long-term management, scientists in the United States report.